Increased Metastatic Colorectal Cancer Virulence Following Chronic KRAS Suppression (ACS-CLINCON 2026) - Sep 22, 2026 - Pres time: Sep 27, 2026; 05:10 PM - 05:21 PM; Location: Room 207B; In Person Only; " CMS3 CRC cell lines (LS180 and LS513) were treated with KRAS inhibitors BI-2865 and RMC-6236 to generate pan-KRAS inhibitor-resistant derivatives...Resistant cells also displayed increased resistance to 5-FU, oxaliplatin, and FOLFIRINOX... Prolonged KRAS inhibition induces EMT and transcriptional reprogramming, driving CMS3 cells toward a CMS4-like phenotype through SRC-FAK pathway. This transition may represent a previously unrecognized mechanism of KRAS inhibitor resistance and disease progression in CRC."
Metastases • Colorectal Cancer • Oncology • Solid Tumor • CDH1 • CDH2 • CLDN1 • KRAS • TGFB1 • ZEB1
|
|
Lauren Tyler, MD; Alex Kim, MD; Zhuan Zhou; PhD
|